FDA Issues CRL to Sobi for NASP in Uncontrolled Gout
Sobi NASP CRL: FDA Rejected the Control System | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Manufacturing Long Read Pharma Market Case Studies Witfire Elite View FDA Issues CRL to Sobi for NASP in Uncontrolled Gout Over CMC and CMO Deficiencies FDA gave Sobi a Complete Response Letter for NASP in uncontrolled gout, but the letter did…
Trending News
Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib
Revolution Medicines Daraxonrasib: The $4.3B Autopsy | Witfire Elite View Witfire Elite Oncology…
Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection
Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks
The stock market is now looking at the US-Israel-Iran conflict through a sharper…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
The US-Israel-Iran war is affecting pharma stocks, drug supply chains, logistics costs, cold-chain…
Editorial picks
FDA Issues CRL to Sobi for NASP in Uncontrolled Gout
Sobi NASP CRL: FDA Rejected the Control System | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Manufacturing Long Read Pharma Market Case Studies Witfire Elite View FDA Issues CRL to Sobi for NASP in Uncontrolled Gout Over CMC and CMO Deficiencies FDA gave Sobi a Complete Response…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk
Categories
Investments
business news
Entrepreneurship
Startups
June, 2026
Chokepoints & Catalysts — Vol. I, No. 1
Five intelligence-led analyses on how FDA decisions, geopolitical chokepoints, and policy shifts are repricing global pharma—covering GSK’s Nuvalent acquisition, Replimune’s RP1, India’s CRO opportunity, API dependence, and Lilly’s Germany investment cut.
Around The World
Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib
Revolution Medicines Daraxonrasib: The $4.3B Autopsy | Witfire Elite View Witfire Elite Oncology Strategy Case Studies Financing Long Read Pharma Market Case Studies Witfire Elite View Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib Phase 3 Data, Capital Structure and the Cost of Independence Revolution Medicines has not eliminated acquisition interest. It has eliminated the financial urgency that could…
Pharma News
FDA Issues CRL to Sobi for NASP in Uncontrolled Gout
Sobi NASP CRL: FDA Rejected the Control System | Witfire Elite View Witfire Elite FDA & Regulatory Case…
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3 | Witfire Elite View Witfire Elite Competitive Strategy Case…
Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib
Revolution Medicines Daraxonrasib: The $4.3B Autopsy | Witfire Elite View Witfire Elite Oncology Strategy Case Studies Financing Long…